ScholarX: AHN, JIN SEOK

Detailed Information

AHN, JIN SEOK (안진석)

Medicine (Medicine)

Research Area

Tel 02-3410-3453
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Nonsmall cell lung cancer:36||nonsmall cell lung cancer:26||NSCLC:24||Breast cancer:19||Breast neoplasms:17||breast cancer:14||Epidermal growth factor receptor:14||Chemotherapy:12||Immunotherapy:10||Lung cancer:9||Metastatic breast cancer:9||Prognosis:8||EGFR:8||HER2:8||Neoadjuvant chemotherapy:8||Osimertinib:7||Breast neoplasm:7||T790M:7||Nonsmallcell lung cancer:7||Quality of life:7||EGFR mutation:7||Recurrence:7||Neoplasms:7||Survival:6||immune checkpoint inhibitor:6||Immunohistochemistry:6||Immune checkpoint inhibitor:6||Mutation:6||Nonsmallcell lung carcinoma:6||3:6||Pemetrexed:6||immunotherapy:5||small cell lung cancer:5||Lazertinib:5||PDL1:5||Pathologic complete response:5||Non–small cell lung cancer:5||overall survival:5||osimertinib:5||Korea:5||Gefitinib:5||Epidemiology:5||Carcinoma:5||chemotherapy:5||Nonsmall cell lung carcinoma:5||Epidermal growth factor receptor (EGFR):5||neoadjuvant chemotherapy:5||Brain metastases:5||Guideline:5||ROS1:5||cisplatin:4||Lung neoplasms:4||Acquired resistance:4||lung cancer:4||prognosis:4||metastatic breast cancer:4||KRAS:4||Trastuzumab:4||Adenocarcinoma:4||Brain metastasis:4||nextgeneration sequencing:4||Triplenegative breast cancer:4||ErbB receptors:4||nonsmallcell lung cancer:4||nonsmall cell lung cancer:4||Radiation therapy:4||Cisplatin:4||Neoplasm metastasis:4||Biomarker:4||Erlotinib:4||EGFR TKI:4||Nonsmall cell lung cancer (NSCLC):4||Chemoradiotherapy:4||Adjuvant chemotherapy:3||Cardiotoxicity:3||Tyrosine kinase inhibitor (TKI):3||Adjuvant radiotherapy:3||Compliance:3||Realworld data:3||Stage IIIA:3||Receptor:3||adenocarcinoma:3||Pembrolizumab:3||BRCA1:3||pemetrexed:3||Thymoma:3||triplenegative breast cancer:3||Neversmokers:3||Small cell lung cancer:3||Metastasis:3||Overall survival:3||lung adenocarcinoma:3||Validation:3||NonSmall Cell Lung Cancer:3||Leptomeningeal metastases:3||Alectinib:3||Afatinib:3||Cancer:3||lung:3||Lung:3||survival:3||Palliative chemotherapy:3||brain metastasis:3||Cohort:3||cancer:3||Response criteria:3||Durvalumab:3||gefitinib:3||Thymic epithelial tumor:3||Crizotinib:3||Radiotherapy:3||triple negative breast cancer:2||computational biology:2||tumor microenvironment:2||Nomogram:2||crizotinib:2||tyrosine kinase inhibitor:2||uncommon EGFR mutation:2||Resistance:2||vandetanib:2||Response:2||Etirinotecan pegol:2||volumetry:2||5:2||<:2||prognostic factor:2||Docetaxel:2||epidermal growth factor:2||epidermal growth factor receptor:2||epidermal growth factor receptor (EGFR):2||Aprepitant:2||Ki67:2||81:2||Knowledge:2||Small cell lung carcinoma:2||Drug therapy:2||Outcomes:2||Oxaliplatin:2||Female:2||Circulating tumor DNA:2||Fulvestrant:2||92:2||hepatitis B virus:2||PDL1 expression:2||Leptomeningeal metastasis:2||Survivorship:2||Dynamics:2||hyperprogression:2||ifosfamide:2||T cell:2||Automatically updated:2||immune checkpoint inhibitors:2||Analgesics:2||PROCTCAE:2||CD39:2||Paclitaxel:2||Pain:2||Palbociclib:2||TP53:2||Targeted therapy:2||leptomeningeal metastases:2||liquid biopsy:2||Lymph node:2||236:2||Anaplastic lymphoma kinase:2||maintenance therapy:2||Thymidylate synthase:2||Patientreported outcomes:2||HER2 mutation:2||HER2 positive:2||MEK inhibitor:2||Treatment outcome:2||Trimodality therapy:2||Triple negative:2||HER2overexpressing breast cancer:2||HER2positive breast cancer:2||Phosphatidylinositol 3kinases:2||nonsmall cell lung cancer (NSCLC):2||HER3:2||Maintenance therapy:2||12:2||4:2||Pleomorphic carcinoma:2||Tumor mutation burden:2||paclitaxel:2||AZD1775:2||pathologic complete response:2||Cancer pain:2||ALK:2||pazopanib:2||Pralsetinib:2||peripheral blood:2||Predictive factor:2||Tyrosine kinase inhibitor:2||Tyrosine kinase inhibitors:2||Hormone receptor:2||Premenopausal:2||AZD9291:2||Molecular subtype:2||Mortality:2||Vomiting:2||primary resistance:2||Human epidermal growth factor receptor 2:2||Prognostic factor:2||elderly:2||Prognostic factors:2||Entrectinib:2||progressionfree survival:2||EpCAM:2||Hyperprogressive disease:2||radiotherapy:2||adjuvant chemotherapy:2||recurrence dynamics:2||Epidermal growth factor:2||Progressionfree survival:2||afatinib:2||N2:2||residual cancer burden:2||DNA sequencing:2||NKTR102:2||salvage chemotherapy:2||Immunerelated adverse event:2||Pulmonary pleomorphic carcinoma:2||Nausea:2||smallcell lung cancer:2||biomarker:2||Neoadjuvant:2||brain:2||brain metastases:2||RET fusion:2||RET rearrangement:2||Neoadjuvant concurrent chemoradiotherapy:2||Radiosurgery:2||Ramosetron:2||Neoadjuvant therapy:2||ErbB2 receptor:2||L1:1||LAG3:1||Large cell neuroendocrine carcinoma:1||Left ventricular ejection fraction:1||Leptomeningeal:1||Leptomeningeal carcino:1||Leptomeningeal carcinomatosis:1||Leptomeningeal seeding:1||Limitedstage:1||Liquid biopsy:1||Local neoplasm recurrence:1||Local recurrence:1||Local therapy:1||Locally advanced nonsmall cell lung cancer:1||Locoregional recurrence:1||Long survival outcomes:1||Lung Neoplasms:1||Lymph node metastasis:1||Lymph node ratio:1||Lymphatic:1||Lymphatic irradiations:1||Lymphovascular invasion:1||MAID:1||MDSC:1||MET Exon 14 Skipping:1||MMP1:1||MRI:1||Machine learning:1||Maintenance:1||Masaoka&apos:1||Matrix metalloproteinase:1||Measurement scale:1||Mechani:1||Medical big data:1||Mesenchymalepithelial transtion tyrosine kinase receptor:1||Metachronous:1||Metastases:1||Metastatic breast cancer (MBC):1||Mobile application:1||Molecular profiling:1||Molecular response:1||Molecular sequencing:1||Mouse:1||Mucin 1 expressi:1||Multimodality:1||Mutant EGFR:1||Myeloid Derived Suppressor Cell:1||N:1||N1 adenocarcinoma:1||N1 disease:1||N2 disease:1||N3:1||NEUROD1:1||NP28673:1||NP28761:1||NTRK:1||Naloxone:1||Neoadjuvant TCHP regimen:1||Nerve growth factor:1||Neuroendocrine tumor:1||Neuropathic pain:1||NonSmallCell Lung:1||Nonadenocarcinoma:1||Noncancer pain:1||Nonsmall cell lung:1||Nonsmall cell lung cancer with N2 disease:1||Nonsmallcell lung:1||Nonsquamous nonsmall cell lung cancer:1||Non–small cell lung carcinoma:1||Non–smallcell lung cancer:1||Non–smallcell lung cancer (NSCLC):1||Non–smallcell lung carcinoma:1||Obesity:1||Objective measured:1||Oligorecurrence:1||Oncology:1||Ondansetron:1||Onycholysis:1||Oxycodone:1||PAM50:1||PD1:1||PD1 blockade:1||PD1 inhibitors:1||PD1PDL1 blockade:1||PD1/PDL1:1||PDL1 inhibitors:1||PDE5 inhibitor:1||PERLA:1||PET CT:1||PF06463922:1||PFS:1||PI3K alpha inhibitor:1||PIK3CA:1||POU2F3:1||PROMIS:1||PROMIS29:1||PTEN:1||Palliative:1||Palonosetron:1||Pathological complete response:1||Patient Comfort:1||Patient selection:1||PatientCentered Care:1||PatientReported Outcomes:1||PatientReported Outcomes Measurement Information System:1||Patientreported outcome (PRO):1||Patterns of failure:1||Performancebased task ability:1||Peripheral blood human mononuclear cells:1||Permanent chemotherapyinduced alopecia:1||Persistent N2:1||Pertuzumab:1||Pharmacokinetics:1||Phase II trial:1||Phospholipase D:1||Platinum:1||Platinum compound:1||Platinum doublet:1||Platinumbased combination chemotherapy:1||Pooled analysis:1||Population characteristics:1||Positron emission tomography:1||Positron emission tomography (PET):1||Postmenopause:1||Practical guide:1||Predictivity:1||Predictor:1||Predictors:1||Preoperative chemothe:1||Prevalence:1||Primary systemic therapy:1||Professional education:1||Progesterone receptors:1||Prognostic biomarker:1||Prognostic group:1||Program development:1||Program evaluation:1||Programmed Cell Death 1 Receptor:1||Programmed cell death 1 receptor:1||Programmed cell death protein(ligand) 1:1||Programmed cell deathligand 1:1||Programmed deathligand 1:1||Prophylactic cranial irradiation:1||Proportion:1||Prospective study:1||Protocols & guidelines:1||Proton beam therapy:1||Psychosocial support:1||Pulmonary adenocarcinoma:1||Pulmonary embolism:1||Pulmonary function:1||Quinazolines:1||RANOLM:1||RECIST:1||RECIST 1.1:1||RET:1||RETrearrangement:1||Randomized Controlled Trial:1||Randomized controlled trial:1||Real world evidence:1||Realtime updated system:1||Regional:1||Relapse pattern:1||Relapsefree survival:1||Relative survival rate:1||Repeat biopsy:1||Repeat tests:1||Resectability:1||Resistance mechanism:1||Return to work:1||S1:1||SCLC:1||SNPs:1||SUVmax:1||Safety:1||Salvage concurrent chemoradiation therapy:1||Salvage therapy:1||Segmental mastectomy:1||Single nucleotide polymorphism:1||Singlecell RNA sequencing:1||Skeletalrelated event:1||Skin:1||Skin changes:1||Small biopsy:1||Small cell lung cancer (SCLC):1||Smallcell lung cancer:1||Smoking:1||Smoking status:1||Soft tissue infiltration:1||Somatic copy number alteration:1||Spinal cord compression:1||Squamous cell:1||Squamous cell lung cancer:1||Stage III:1||Stage IIIAN2:1||Stereotactic radiosurgery (SRS):1||Stomach neoplasms:1||Structured query language:1||Subcutaneous:1||Suboptimal response:1||Subtype:1||Supraclavicular recurrence:1||Surgery:1||Surveys:1||Survival outcomes:1||Symptom monitoring:1||Systemic chemotherapy:1||T cell senescence:1||TDM1:1||TLymphocytes:1||T790M mutation:1||T790 M mutation:1||TCHP:1||TGFbeta:1||TGFα:1||TKI:1||TNM stage:1||TNM staging:1||Target therapy:1||Targeted nextgeneration sequencing:1||Targeted sequencing:1||Thirdgeneration EGFR tyrosine kinase inhibitor:1||Thymic Epithelial Tumors:1||Thymic carcinoma:1||Thymic epithelial tumor (TET):1||Thymic epithelial tumors:1||Thymic tumor:1||Thymidine phosphorylase:1||Thymus:1||Thyroid:1||Tolllike receptor agonist:1||Tool development:1||Topical lotion:1||Toxicity:1||Transdermal buprenorphine:1||Transient asymptomatic pulmonary opacities:1||Treatment:1||Treg cells:1||Triple negative breast cancer:1||Triple negative breast cancer (TNBC):1||Triple negative breast neoplasms:1||Triplenegative breast neoplasms:1||Tuberculosis:1||Tumor Associated Macrophage:1||Tumor Biomarkers:1||Tumor lysis syndrome:1||Tumor marker:1||Tumor microenvironment:1||Tumor mutational burden (TMB):1||Tumor response assessment:1||Tumor suppressor protein p53:1||Tumorinfiltrating lymphocytes:1||Tumour biomarkers:1||Tumour mutation burden:1||Twost:1||Tyrosine:1||Tyrosinekinase inhibitor:1||UICC 7th TNM stage:1||Uncommon EGFR:1||Unresectable locally advanced non–small cell lung cancer:1||Unsuspected N2 lymph node:1||VP shunt:1||Vandetanib:1||Vascular Access Devices:1||Vortex keratopathy:1||WHO histologic classification:1||Wee1:1||White ethnicity:1||Whole brain radiation therapy (WBRT):1||Women:1||Young breast cancer:1||acquired resistance:1||actionable genetic alterations:1||adavosertib:1||adjuvant cohort:1||adjvuant therapy:1||afainib:1||alectinib:1||allogeneic:1||amivantamab:1||amphiregulin:1||anaplastic lymphoma kinaserearranged (ALK+) NSCLC:1||antiPD1:1||antitumor effects:1||arsenical:1||atezolizumab:1||autoimmune disease:1||autologous HSCT:1||autologous hematopoietic stem cell transplantation:1||bevacizumab:1||biomarkers:1||breast neoplasm:1||ckit:1||cmet:1||cancer biology:1||cancer pain:1||capecitabine:1||carboplatin:1||cardiovascular event:1||casefatality rate:1||cell adhesion molecules:1||cellfree DNA:1||central nervous system:1||ceralasertib:1||chemokine (CXC motif) ligand 13:1||chemoradiotherapy:1||chemotherapynaive:1||chronic GVHD:1||circadian rhythm:1||circulating tumor DNA:1||clinical grading:1||concurrent chemoradiotherapy:1||dacomitinib:1||de novo:1||death:1||deep vein thrombosis:1||diffuse large B cell lymphoma:1||direct oral anticoagulants:1||disease free survival:1||docetaxel:1||dovitinib:1||droplet digital PCR:1||drug therapy:1||eHealth:1||eeliability:1||ejection fraction:1||endocrine therapy:1||entrectinib:1||epidermal growth factor receptor mutant nonsmallcell lung cancer:1||epidermal growth factor receptor mutation:1||epidermal growth factor receptortyrosine kinase inhibitors (EGFRTKIs):1||erectile dysfunction:1||erlotinib:1||esophageal cancer:1||ethnic difference:1||excesion repair crosscomplementation group 1 (ERCC1):1||exon 20:1||exosomes:1||expression assay:1||extensive:1||extracellular vesicles:1||extracranial disease control:1||fibroblast growth factor receptor:1||fibroblast growth factor receptor 1 (FGFR1) amplification:1||ficlatuzumab:1||first line:1||fluorescence:1||fragmentome:1||gastric cancer:1||gene:1||genetic alteration:1||glycerophospholipids:1||hepatitis:1||hepatitis B virus reactivation:1||histologic type:1||homologydependent recombination deficiency:1||hormone receptor:1||hormone receptor positive:1||hormone receptor positive (HR+):1||human:1||human leukocyte antigen:1||idiopathic thrombocytopenic purpura:1||immune check point inhibitor:1||immune checkpoint:1||immune checkpoint therapy:1||immune profiling:1||immune related response:1||immune signature:1||immunecheckpoint inhibitor:1||immunology:1||immunosuppressive treatment:1||intensive chemotherapy:1||interstitial lung disease:1||intestinal lymphoma:1||intracavernosal injection:1||intracranial radiotherapy:1||intravenous immunoglobulins:1||irinotecan:1||isolated locoregional recurrence:1||kras:1||latestage biopsy:1||leptomeningeal disease:1||limited disease (LD):1||locoregional r:1||lowmolecularweight heparin:1||mHealth:1||machine learning:1||mechanism:1||metastatic:1||metastatic breast cancer (MBC):1||mitomycin C:1||molecular subtype:1||molecular subtypes:1||monotherapy:1||mortality:1||multiplex IHC:1||mutation:1||myeloidderived suppressor cell:1||nCounter mRNA expression assay:1||neoadjuvant chemotherapy:1||neoadjuvant CCRT:1||neoadjvant chemotherapy:1||neuroendocrine tumors:1||neversmoker:1||next generation sequencing (NGS):1||nimotuzumab:1||non small cell lung cancer (NSCLC):1||nonsmallcell lun:1||nonsmallcell lung:1||non–small cell lung cancer:1||objective response rate:1||oesophageal cancer:1||olaparib:1||omics:1||outcome:1||p53:1||pain management survey:1||palbociclib with letrozole:1||patientreported outcomes:1||pattern of recurrence:1||pd1 inhibitor:1||pembrolizumab:1||pertuzumab:1||pharmacogenetics:1||phase II pooled analysis:1||phosphorylated signal transducer and activator of transcription 3:1||physician:1||plasma:1||platinum chemotherapy:1||poly(ADPribose) polymerase:1||postremission therapy:1||poziotinib:1||precision medicine:1||precursor cell lymphoblastic leukemialymphoma:1||prediction model:1||predictive biomarkers:1||predictor:1||pregnancy:1||progesterone receptor:1||prognostic biomarker:1||prognostic model:1||programmed death ligand 1 (PDL1):1||prospective cohort:1||pulmonary embolism:1||quality of life:1||radiation pneumonitis:1||real time prediction:1||realworld data:1||rebiopsy:1||recurrence model:1||recurrence pattern:1||refractory:1||refractory metastatic breast cancer:1||relapse:1||resection:1||residual proliferative cancer burden:1||response rate:1||response signature:1||risk stratification:1||s staging system:1||salvage regimen:1||second line treatment:1||sedation:1||singlecell RNA sequencing:1||small cell lung cancer (SCLC):1||small cell lung carcinoma:1||soluble ICAM1:1||squamous cell lung cancer:1||stage smallcell lung cancer:1||surgery:1||surveillance:1||survival outcome:1||symptom:1||symptomatic adverse events:1||systems biology:1||targeted nextgeneration sequencing:1||targeted sequencing:1||targeted therapy:1||taxane:1||telomere:1||tertiary lymphoid structure:1||thirdgeneration TKI:1||threeweek schedule:1||thymic cancer:1||thymic carcinoma:1||thymic epithelial tumour (TET):1||thymidine phosphorylase (TP):1||thymidine synthase (TS):1||thymoma:1||time to progression:1||transcriptomics:1||transient asymptomatic pulmonary opacities:1||trastuzumab:1||treatment practices:1||tuberculosis:1||tumor:1||tumor mutation burden:1||tumor response:1||tyrosine kinase inhibitors:1||tyrosinekinase inhibitor:1||uncommon EGFR:1||undertreatment of pain:1||validity:1||vascular endothelial growth factor A:1||vascular endothelial growth factor receptor 1:1||venous thromboembolism:1||vistusertib:1||whole exome sequencing (WES):1||wild type:1||불안:1||불편감:1||암:1||중심정맥관:1||1:1||18FFDG:1||1st line:1||2:1||26143675592760:1||2614922769:1||2614923532237076502700:1||26149235322373:1||283217:1||312:1||3282330646143760:1||328246447627374510025:1||3rd generation:1||3rd generation EGFR TKI:1||4th generation:1||= 1 cm Invasive breast cancer:1||= 1 cm i:1||A proliferationinducing ligand:1||AJCC 8th edition:1||ALK inhibitor:1||ALK positive NSCLC:1||ALKinhibitor:1||ALKpositive:1||AML:1||ASCL1:1||ATIC:1||AZD2811NP:1||Acute kidney injury:1||Adaptive Immunity:1||Adjuvant:1||Adjuvant concurrent chemoradiotherapy:1||Adjuvant treatment:1||Adoption:1||Advanced breast cancer:1||Advanced nonsmall cell lung cancer:1||Adverse effects:1||Adverse event management:1||Aged:1||Alopecia:1||Altered appearance:1||Amivantamab:1||AmpliSeq:1||Ampliseq:1||Anaplastic:1||Anaplastic lymphoma kinase (ALK):1||Angiogenesis:1||Anthracycline and taxanepretreated:1||AntiHER2 targeted therapy:1||Antiangiogenic therapy:1||Antibodydrug conjugate:1||Anticancer:1||Anticoagulation:1||Antiemetics:1||Anxiety:1||Apoptosis:1||Asian:1||Asymptomatic brain metastases in NSCLC:1||Atezolizumab:1||Axillary lymph node:1||BIM Deletion Polymorphism:1||BIM deletion polymorphism:1||BRCA mutation:1||BRCA2:1||Bevacizumab:1||Big data:1||Biology:1||Body image:1||Body mass index:1||Bone:1||Botanical:1||Brain:1||Breast Neoplasms:1||Breast cancer subtype:1||Breast cancer survivors:1||Breast carcinoma:1||Brigatinib:1||Bulky nodal involvement:1||CXC motif chemokine ligand 13:1||C797S mutation:1||CA 153:1||CD8(+) T cells:1||CDK4/6 inhibitor:1||CDW:1||CHEMOTHERAPY:1||CNS metastases:1||COPD:1||CSIHC4:1||CXCL13:1||California Cancer Registry:1||Cancer patients:1||Capecitabine:1||Capecitabine monotherapy:1||Carcinoid tumor:1||Carcinoma, Nonsmallcell lung:1||Casecontrol study:1||Cellfree DNA (cfDNA):1||Central Nervous System:1||Characteristic:1||Chemotherapyinduced skin change:1||Chronic myelogenous leukemia:1||Chronic pain management:1||Cigarette smoking:1||Circulating tumor DNA (ctDNA):1||Classificatio:1||Classification:1||Clinical outcome:1||Clinical trial:1||Combination strategy:1||Combination therapy:1||Comparison:1||Compassionate use pragram:1||Concurrent chemoradiation therapy:1||Concurrent chemoradiotherapy:1||Concurrent chemoradiotherapy:1||Consolidation:1||Constipation:1||Copy number:1||Corneal epithelial change:1||Coronavirus disease 2019 outbreak (COVID19 outbreak):1||Costs and cost analysis:1||Cyclin D1:1||DGGE:1||DNA damage and response:1||DNA damage response:1||Dacomitinib:1||Datopotamab deruxtecan:1||Definitive CCRT:1||Derivatives:1||Digital health literacy:1||Digital health technology literacy:1||Distress:1||Dose escalation:1||Dostarlimab:1||Double primary tumor:1||Dovitinib:1||Dryness:1||Dullness:1||Durable clinical benefit:1||Durable responders:1||Durable response:1||Dyslipidemia:1||EGER messenger RNA (mRNA):1||EGF:1||EGFR T790M:1||EGFR T790Mpositive nonsmall cell lung cancer (NSCLC):1||EGFR inhibitor:1||EGFR mutant NSCLC:1||EGFR tyrosine kinase inhibitor:1||EGFRTKIs:1||EGFRTKIs targeted therapy:1||EGFRmutated NSCLC:1||EGFRmutation:1||EGFR/MET ratio:1||EGFT TKI:1||ER:1||ER status:1||ERK inhibitor:1||Early failure:1||Early stage:1||Education:1||Employment:1||Endocrine therapy:1||Epidermal growth:1||Epidermal growth factor receptor (EGFR) mutant nonsmall cell lung cancer (NSCLC):1||Epidermal growth factor receptor mutation:1||Epidermal growth factor receptor tyrosine kinase inhibitors:1||Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs):1||Esophageal neoplasms:1||Estrogen receptors:1||Ets1:1||Exon 20 insertion:1||Exosomes:1||Extracellular vesicles:1||F18FDG PET/CT:1||F18fluorodeoxyglucose (FDG):1||FGFR:1||FGFR inhibitor:1||Family history:1||Firstline:1||Firstline therapy:1||Fracture:1||GGH:1||Gamma Knife:1||Gamma knife radiosurgery:1||Gemcitabine:1||Genes:1||Genetic counseling:1||Genetic heterogeneity:1||Genome:1||Global longitudinal strain:1||HER pathway:1||HER2:1||HER2 negative:1||HER2 amplification:1||HER2 expression:1||HER2 positivity:1||HER2+breast cancer:1||HM61713:1||Hair density:1||Hair thickness:1||Healthcare providers:1||Heparin:1||Her2:1||Herceptin:1||Histologic transformation:1||Hormonal receptor:1||Hormone receptor positive:1||Hormone receptorpositive breast cancer:1||Hormone receptors:1||Human epidermal growth factor receptor 2 (HER2):1||Hydrating nail solution:1||Hyperuricemia:1||IL10:1||ITMIG:1||Imaging genomics:1||Imatinib:1||Immune checkpoint inhibitors:1||Immune gene signature:1||Immunecheckpoint inhibitor:1||Immunerelated adverse events:1||Immunerelated response:1||Immunosuppression:1||In situ hybridization:1||Incidence:1||Interstitial lung disease:1||Intratumoral heterogeneity:1||Intrinsic subtype:1||Invasive micropapillary carcinoma:1||Irinotecan:1||JAK1 pathway:1||KML001:1||Ki67 proliferation index:1||Korean:1||Korean Translation:1||Korean ethnicity:1||

STATISTICS: Total View:; Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE